Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02807805Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerTreatment
NCT03649841Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate CancerTreatment
NCT04267887Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate CancerTreatment
NCT03999515Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTreatment
NCT03821792Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerTreatment
NCT03012321Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsTreatment
NCT03833921Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerTreatment
NCT04262154Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerTreatment